MorphoSys AG Announces Clinical Milestone in Antibody Program -- Fourth HuCAL-based Antibody to Begin Clinical Trials

MARTINSRIED, Germany, Sept. 18, 2007 (PRIME NEWSWIRE) -- MorphoSys AG (Frankfurt:MOR) (Prime Standard Segment) announced today that a HuCAL GOLD-derived fully human antibody against a non-disclosed target molecule in the therapeutic area of oncology has been advanced to a Phase 1 clinical trial. This Investigational New Drug application filing, resulting from MorphoSys collaboration with Novartis, triggers a clinical milestone payment to MorphoSys.

Back to news